Sherman Oaks, CA – June 14, 2023 T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the management will present virtually at the following upcoming healthcare conferences:
11th Annual Immuno-oncology Summit, August 7-9th in Boston
- “Emerging Cell-based Immunotherapies” venue on Aug 8. Brochure PDF – https://immuno-oncologysummit.com/docs/librariesprovider48/brochures/23/Immuno-Oncology-Summit-Final-Brochure-2023.pdf
8th CAR-TCR Summit, Aug 29th-Sept 1st in Boston
- “De-risking TCRs to Ensure Safety”. Find out more here: https://ter.li/plsmuo #CARTCR #immunotherapy #celltherapy #celltherapies #cellandgene #immunology
About T-Cure Bioscience, Inc.
T-Cure Bioscience, Inc. is an innovative immuno-oncology company committed to delivering effective and durable cell therapies for the treatment of cancer. The Company focuses on isolating high avidity TCR that can be used to engineer a patient’s T cells to effectively target and destroy solid tumors. The Company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1 and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma.
More information is available at www.T-Cure.com.
Contacts
T-Cure Bioscience, Inc. IR & Media Contact
IR@T-cure.com
